MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome
详细信息 查看全文
- 作者：Jennifer A Byrne (1) (2)
Sanaz Maleki (3)
Jayne R Hardy (1)
Brian S Gloss (3)
Rajmohan Murali (4) (5)
James P Scurry (6)
Susan Fanayan (1) (2)
Catherine Emmanuel (7) (8)
Neville F Hacker (10) (9)
Robert L Sutherland (11) (3)
Anna deFazio (7) (8)
Philippa M O'Brien (11) (3) - 刊名：BMC Cancer
- 出版年：2010
- 出版时间：December 2010
- 年：2010
- 卷：10
- 期：1
- 全文大小：2055KB
- 参考文献：1. Bast RC Jr, Hennessy B, Mills GB: The biology of ovarian cancer: new opportunities for translation. / Nat Rev Cancer 2009, 9:415鈥?8. CrossRef
2. Shih I-M, Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. / Am J Pathol 2004, 164:1511鈥?. CrossRef
3. Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew Y-E, Livnat Y, St. Heaps L, Peters G, Byth K, Karlan BY, Slamon DJ, Harnett P, deFazio A: Tumor Protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. / Int J Cancer 2005, 117:1049鈥?4. CrossRef
4. Myllykangas S, Himberg J, Bohling T, Nagy B, Hollmen J, Knuutila S: DNA copy number amplification profiling of human neoplasms. / Oncogene 2006, 25:7324鈥?2. CrossRef
5. Baudis M: Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. / BMC Cancer 2007, 7:226. CrossRef
6. Nowee ME, Snijders AM, Rockx DA, de Wit RM, Kosma VM, H盲m盲l盲inen K, Schouten JP, Verheijen RH, van Diest PJ, Albertson DG, Dorsman JC: DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification. / J Pathol 2007, 213:46鈥?5. CrossRef
7. Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, Choong DY, Campbell IG: High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. / Clin Cancer Res 2007, 13:4731鈥?. CrossRef
8. Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchi貌 C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, El-Bahrawy M, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A, Reis-Filho JS: PPM1 D is a potential therapeutic target in ovarian clear cell carcinomas. / Clin Cancer Res 2009, 15:2269鈥?0. CrossRef
9. Wilson SH, Bailey AM, Nourse CR, Mattei MG, Byrne JA: Identification of MAL2, a novel member of the mal proteolipid family, through interactions with TPD52-like proteins in the yeast two-hybrid system. / Genomics 2001, 76:81鈥?8. CrossRef
10. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PF, Tibshirani R, Botstein D, Borresen-Dale AL, Brown PO: Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. / Proc Natl Acad Sci USA 2002, 99:12963鈥?. CrossRef
11. Paik S, Kim C-K, Song Y-K, Kim W-S: Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. / Nature Clin Pract Oncol 2005, 2:246鈥?4. CrossRef
12. Shehata M, Bi猫che I, Boutros R, Weidenhofer J, Fanayan S, Spalding L, Zeps N, Byth K, Bright RK, Lidereau R, Byrne JA: Non-redundant functions for tumor protein D52-like proteins support specific targeting of TPD52. / Clin Cancer Res 2008, 14:5050鈥?0. CrossRef
13. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, Jaffee E, Ryu B, Jones J, Eshleman JR, Yeo CJ, Cameron JL, Kern SE, Hruban RH, Brown PO, Goggins M: Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. / Am J Pathol 2003, 162:1151鈥?2. CrossRef
14. Heidenblad M, Lindgren D, Veltman JA, Jonson T, Mahlam盲ki EH, Gorunova L, van Kessel AG, Schoenmakers EF, H枚glund M: Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications. / Oncogene 2005, 24:1794鈥?01. CrossRef
15. Lowe AW, Olsen M, Hao Y, Lee SP, Taek Lee K, Chen X, van de Rijn M, Brown PO: Gene expression patterns in pancreatic tumors, cells and tissues. / PLoS ONE 2007, 2:e323. CrossRef
16. Hoang CD, D'Cunha J, Kratzke MG, Casmey CE, Frizelle SP, Maddaus MA, Kratzke RA: Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. / Chest 2004, 125:1843鈥?2. CrossRef
17. Dasgupta S, Tripathi PK, Qin H, Bhattacharya-Chatterjee M, Valentino J, Chatterjee SK: Identification of molecular targets for immunotherapy of patients with head and neck squamous cell carcinoma. / Oral Oncol 2006, 42:306鈥?6. CrossRef
18. Rohan S, Tu JJ, Kao J, Mukherjee P, Campagne F, Zhou XK, Hyjek F, Alonso MA, Chen YT: Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. / Clin Cancer Res 2006, 12:6937鈥?5. CrossRef
19. S谩nchez-Pulido L, Mart铆n-Belmonte F, Valencia A, Alonso MA: MARVEL: a conserved domain involved in membrane apposition events. / Trends Biochem Sci 2002, 27:599鈥?01. CrossRef
20. de Marco MC, Mart铆n-Belmonte F, Kremer L, Albar JP, Correas I, Vaerman JP, Marazuela M, Byrne JA, Alonso MA: MAL2, a novel raft protein of the MAL family, is an essential component of the machinery for transcytosis in hepatoma HepG2 cells. / J Cell Biol 2002, 159:37鈥?4. CrossRef
21. Shridhar V, Lee J, Pandita A, Itturia S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC Jr, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI: Genetic analysis of early versus late-stage ovarian tumors. / Cancer Res 2001, 61:5895鈥?904.
22. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, Edwards LS, Vanden Bergh PM, Hacker NF, Sutherland RL, O'Brien PM: Overexpression of the cell adhesion molecules DDR1, Claudin 3 and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. / Clin Cancer Res 2004, 10:4427鈥?6. CrossRef
23. Schaner ME, Davidson B, Skrede M, Reich R, Fl酶renes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Trop猫 CG, Kristensen GB, Nesland JM, B酶rresen-Dale AL: Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. / Mol Cancer 2005, 4:26. CrossRef
24. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell DD: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. / Clin Cancer Res 2008, 14:5198鈥?08. CrossRef
25. Rapberger R, Perco P, Sax C, Pangerl T, Siehs C, Pils D, Bernthaler A, Lukas A, Mayer B, Krainer M: Linking the ovarian cancer transcriptome and immunome. / BMC Syst Biol 2008, 2:2. CrossRef
26. Chen Y, Zheng B, Robbins DH, Lewin DN, Mikhitarian K, Graham A, Rumpp L, Glenn T, Gillanders WE, Cole DJ, Lu X, Hoffman BJ, Mitas M: Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. / Int J Cancer 2007, 120:1511鈥?. CrossRef
27. Shrout J, Yousefzadeh M, Dodd A, Kirven K, Blum C, Graham A, Benjamin K, Hoda R, Krishna M, Romano M, Wallace M, Garrett-Mayer E, Mitas M: Beta(2)microglobulin mRNA expression levels are prognostic for lymph node metastasis in colorectal cancer patients. / Br J Cancer 2008, 98:1999鈥?005. CrossRef
28. Marazuela M, Alonso MA: Expression of MAL and MAL2, two elements of the protein machinery for raft-mediated transport, in normal and neoplastic human tissue. / Histol Histopathol 2004, 19:925鈥?3.
29. Fanayan S, Shehata M, Agterof AP, McGuckin MA, Alonso MA, Byrne JA: Mucin 1 (MUC1) is a novel partner for MAL2 in breast carcinoma cells. / BMC Cell Biol 2009, 10:7. CrossRef
30. Boutros R, Fanayan S, Shehata M, Byrne JA: The tumor protein D52 family: many pieces, many puzzles. / Biochem Biophys Res Commun 2004, 325:1115鈥?121. CrossRef
31. Shehata M, Weidenhofer J, Thamotharampillai K, Hardy JR, Byrne JA: Tumor protein D52 overexpression and gene amplification in cancer- from a mosaic of microarrays. / Crit Rev Oncogenesis 2008, 14:33鈥?5.
32. Thomas DD, Taft WB, Kaspar KM, Groblewski GE: CRHSP-28 regulates Ca2+-stimulated secretion in permeabilized acinar cells. / J Biol Chem 2001, 276:28866鈥?2. CrossRef
33. Zhang H, Wang J, Pang B, Liang RX, Li S, Huang PT, Wang R, Chung LW, Zhau HE, Huang C, Zhou JG: PC-1/PrLZ contributes to malignant progression in prostate cancer. / Cancer Res 2007, 67:8906鈥?3. CrossRef
34. Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, Yang L, Bright RK: Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. / Mol Cancer Res 2007, 5:133鈥?4. CrossRef
35. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR: Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. / Cancer Res 2006, 66:1354鈥?2. CrossRef
36. Banz C, Ungethuem U, Kuban RJ, Diedrich K, Lengyel E, Hornung D: The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. / Fertil Steril 2009, in press.
37. Wang Y, Wu R, Cho KR, Thomas DG, Gossner G, Liu JR, Giordano TJ, Shedden KA, Misek DE, Lubman DM: Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage. / J Proteome Res 2009, 8:1452鈥?3. CrossRef
38. Lee HK, Hsu AK, Sajdak J, Qin J, Pavlidis P: Coexpression analysis of human genes across many microarray data sets. / Genome Res 2004, 14:1085鈥?4. CrossRef
39. Moon A, Yong HY, Song JI, Cukovic D, Salagrama S, Kaplan D, Putt D, Kim H, Dombkowski A, Kim HR: Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion. / Mol Cancer Res 2008, 6:1544鈥?3. CrossRef
40. Thibodeaux CA, Liu X, Disbrow GL, Zhang Y, Rone JD, Haddad BR, Schlegel R: Immortalization and transformation of human mammary epithelial cells by a tumor-derived Myc mutant. / Breast Cancer Res Treat 2009, 116:281鈥?4. CrossRef
41. Suehiro Y, Sakamoto M, Umayahara K, Iwabuchi H, Sakamoto H, Tanaka N, Takeshima N, Yamauchi K, Hasumi K, Akiya T, Sakunaga H, Muroya T, Numa F, Kato H, Tenjin Y, Sugishita T: Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas. / Oncology 2000, 59:50鈥?. CrossRef
42. Adler AS, Lin M, Horlings H, Nuyten DS, van de Vijver MJ, Chang HY: Genetic regulators of large-scale transcriptional signatures in cancer. / Nat Genet 2006, 38:421鈥?0. CrossRef
43. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF: The prognostic role of a gene signature from tumorigenic breast-cancer cells. / N Engl J Med 2007, 356:217鈥?6. CrossRef
44. Zhang Y, Martens JW, Yu JX, Jiang J, Sieuwerts AM, Smid M, Klijn JG, Wang Y, Foekens JA: Copy number alterations that predict metastatic capability of human breast cancer. / Cancer Res 2009, 69:3795鈥?01. CrossRef
45. Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl PO, Borg A, Karhu R, Tanner M, Tirkkonen M, Isola J: Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. / Cancer Res 2003, 63:8861鈥?.
46. Melchor L, Alvarez S, Honrado E, Palacios J, Barroso A, D铆ez O, Osorio A, Ben铆tez J: The accumulation of specific amplifications characterizes two different genomic pathways of evolution of familial breast tumors. / Clin Cancer Res 2005, 11:8577鈥?4. CrossRef
47. Han W, Han MR, Kang JJ, Bae JY, Lee JH, Bae YJ, Lee JE, Shin HJ, Hwang KT, Hwang SE, Kim SW, Noh DY: Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. / BMC Cancer 2006, 6:92. CrossRef
48. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/497/prepub - 作者单位：Jennifer A Byrne (1) (2)
Sanaz Maleki (3)
Jayne R Hardy (1)
Brian S Gloss (3)
Rajmohan Murali (4) (5)
James P Scurry (6)
Susan Fanayan (1) (2)
Catherine Emmanuel (7) (8)
Neville F Hacker (10) (9)
Robert L Sutherland (11) (3)
Anna deFazio (7) (8)
Philippa M O'Brien (11) (3)
1. Molecular Oncology Laboratory, Children's Cancer Research Unit, The Children's Hospital at Westmead, Westmead, New South Wales, Australia
2. The University of Sydney Discipline of Paediatrics and Child Health, The Children's Hospital, Westmead, New South Wales, Australia
3. Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia
4. Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
5. Discipline of Pathology, The University of Sydney, Camperdown, New South Wales, Australia
6. South East Area Laboratory Service, Prince of Wales Hospital, Randwick, New South Wales, Australia
7. Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia
8. Department of Gynaecological Oncology, Westmead Hospital, Westmead, New South Wales, Australia
10. School of Women's and Children's Health, University of New South Wales, Randwick, Australia
9. Gynaecological Cancer Centre, Royal Hospital for Women, Randwick, New South Wales, Australia
11. St Vincent's Clinical School, University of NSW, Sydney, New South Wales, Australia - ISSN：1471-2407
文摘
Background The four-transmembrane MAL2 protein is frequently overexpressed in breast carcinoma, and MAL2 overexpression is associated with gain of the corresponding locus at chromosome 8q24.12. Independent expression microarray studies predict MAL2 overexpression in ovarian carcinoma, but these had remained unconfirmed. MAL2 binds tumor protein D52 (TPD52), which is frequently overexpressed in ovarian carcinoma, but the clinical significance of MAL2 and TPD52 overexpression was unknown. Methods Immunohistochemical analyses of MAL2 and TPD52 expression were performed using tissue microarray sections including benign, borderline and malignant epithelial ovarian tumours. Inmmunohistochemical staining intensity and distribution was assessed both visually and digitally. Results MAL2 and TPD52 were significantly overexpressed in high-grade serous carcinomas compared with serous borderline tumours. MAL2 expression was highest in serous carcinomas relative to other histological subtypes, whereas TPD52 expression was highest in clear cell carcinomas. MAL2 expression was not related to patient survival, however high-level TPD52 staining was significantly associated with improved overall survival in patients with stage III serous ovarian carcinoma (log-rank test, p < 0.001; n = 124) and was an independent predictor of survival in the overall carcinoma cohort (hazard ratio (HR), 0.498; 95% confidence interval (CI), 0.34-0.728; p < 0.001; n = 221), and in serous carcinomas (HR, 0.440; 95% CI, 0.294-0.658; p < 0.001; n = 182). Conclusions MAL2 is frequently overexpressed in ovarian carcinoma, and TPD52 overexpression is a favourable independent prognostic marker of potential value in the management of ovarian carcinoma patients.